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Introduction
Cancer is a major burden of disease and public health 
concern in world (Keyghobadi et al., 2015; Razi et al., 
2015) among cancers, Bladder cancer is an international 
public health problem (Malats and Real, 2015). According 
to the impact of the cancer on mortality, quality of life 
of patients suffering from the cancer and their families, 
and economic costs are important and remarkable 
issues(Klotz and Brausi, 2015). It is the ninth common 
cancer, the eleventh diagnosed cancer, and the fourteenth 
leading cause of deaths due to cancer worldwide (Ferlay 
et al., 2008). The cancer is considered one of the most 
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Abstract
 Background: Bladder cancer is an international public health problem. It is the ninth most common cancer 
and the fourteenth leading cause of death due to cancer worldwide. Given aging populations, the incidence of 
this cancer is rising. Information on the incidence and mortality of the disease, and their relationship with level 
of economic development is essential for better planning. The aim of the study was to investigate bladder cancer 
incidence and mortality rates, and their relationship with the the Human Development Index (HDI) in the world. 
Materials and Methods: Data were obtained from incidence and mortality rates presented by GLOBOCAN in 
2012. Data on HDI and its components were extracted from the global bank site. The number and standardized 
incidence and mortality rates were reported by regions and the distribution of the disease were drawn in the 
world. For data analysis, the relationship between incidence and death rates, and HDI and its components was 
measured using correlation coefficients and SPSS software. The level of significance was set at 0.05. Results: In 
2012, 429,793 bladder cancer cases and 165,084 bladder death cases occurred in the world. Five countries that had 
the highest age-standardized incidence were Belgium 17.5 per 100,000, Lebanon 16.6/100,000, Malta 15.8/100,000, 
Turkey 15.2/100,000, and Denmark 14.4/100,000. Five countries that had the highest age-standardized death rates 
were Turkey 6.6 per 100,000, Egypt 6.5/100,000, Iraq 6.3/100,000, Lebanon 6.3/100,000, and Mali 5.2/100,000. 
There was a positive linear relationship between the standardized incidence rate and HDI (r=0.653, P<0.001), 
so that there was a positive correlation between the standardized incidence rate with life expectancy at birth, 
average years of schooling, and the level of income per person of population. A positive linear relationship was 
also noted between the standardized mortality rate and HDI (r=0.308, P<0.001). There was a positive correlation 
between the standardized mortality rate with life expectancy at birth, average years of schooling, and the level 
of income per person of population. Conclusions: The incidence of bladder cancer in developed countries and 
parts of Africa was higher, while the highest mortality rate was observed in the countries of North Africa and 
the Middle East. The program for better treatment in developing countries to reduce mortality from the cancer 
and more detaiuled studies on the etiology of are essential. 
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common malignant cancers in the world, so that about 
20 percent of people diagnosed eventually die because 
of the disease(Colombel et al., 2008; Brausi et al., 2011; 
Klotz and Brausi, 2015). Around 900,000 new cases are 
affected by the disease worldwide, 250,000 deaths occur 
per year due to the cancer(Klotz and Brausi, 2015) . 
Bladder cancer, on average, is 3 to 4 times more common 
in men than women. The incidence and prevalence of the 
cancer are seen in the sixth decade of life, especially its 
peak in the seventh and eighth. So is it mainly disease of 
elderly (Malats and Real, 2015).
The highest incidence of bladder cancer in men and 
women was observed in Europe, the United States, and 
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Egypt, respectively. There was the lowest level in Sub-
Saharan Africa, Asia, and South America, respectively. 
The greatest mortality rates were in parts of Europe and 
North Africa, and the lowest in Asia, Central America, and 
Middle Africa. However, the incidence and mortality have 
decreased in many Western countries (North America, and 
West and Northern Europe), but the rates have increased 
in some other European countries (South, Central, and 
East Europe) and developing countries in Asia. This 
pattern is due to differences in risk factors for bladder 
cancer (tobacco epidemic, changes in coding practices, the 
prevalence of Schistosoma Haematobium, especially in 
Africa, and occupational exposures) (Chavan et al., 2014). 
The differences in risk factors are the most important 
reason for the difference in the incidence of and deaths 
from bladder cancer in the world. Risk factors for bladder 
cancer include smoking (responsible for 50% of bladder 
cancer and 65% of invasive bladder cancer (Klotz and 
Brausi, 2015)), infection with Schistosoma Haematobium, 
occupational exposures to aromatic amines and polycyclic 
aromatic hydrocarbons (Silverman et al., 2006; Burger 
et al., 2013), and other possible factors such as diet, 
environmental pollution, and genetic predisposition; 
while cigarette smoking is the dominant cause of bladder 
cancer in the United States and Schistosoma Haematobium 
the leading cause in most parts of Africa (Parkin, 2006; 
Burger et al., 2013). 
Bladder cancer is highly preventable (Burger et al., 
2013). Therefore, the urologists can easily affect the 
prevention of the cancer through interaction with their 
patients, primary care physicians and society (Klotz and 
Brausi, 2015). The Human Development Index (HDI) is a 
useful classification to compare the cancer globally (Bray 
et al., 2012; Ghoncheh et al., 2015). As a result, countries 
are classified in to 4 levels, low, medium, high and very 
high, by education, life expectancy, and national income. 
Although communicable diseases and nutrition are 
common causes of death in countries with a low HDI, Non-
communicable diseases such as cancer have overtaken 
(Wagner and Brath, 2012). It is predicted that the cancer 
burden in the world has increased from 12.7 million new 
cases in 2008 to 22.2 million by 2030 (Bray et al., 2012). 
It shows an increase in population and changes in the age 
distribution, the incidence, prevalence, and risk factors. 
For example, open tobacco use in low- and middle-income 
countries leads to a major effect on the cancer burden in 
the coming decades (Giovino et al., 2012). Several studies 
have shown that survival differences are associated with 
socioeconomic status of the patients (Coleman et al., 
2001; Brookfield et al., 2009; Trinh et al., 2012). People 
with low socio-economic status experience lower survival 
due to reduced access to health care, biology of the 
disease, environmental factors, exposure to tobacco, and 
health habits (Shackley and Clarke, 2005). Persons with 
extensive knowledge expose lower to bladder cancer risk 
factors, including smoking. This leads to lower bladder 
cancer in them (Yang et al., 2010). 
The information on the incidence and mortality of 
the disease, and its distribution in terms of geographical 
areas is essential for further studies and better plan for the 
prevention. There is no study to evaluate the incidence 
and mortality from the cancer in the world. Considering 
the relationship between the development and incidence 
and mortality from the cancer, the aim of the study was to 
investigate bladder cancer incidence and mortality rates, 
and their relationship with the HDI in the world. 
Materials and Methods
This study was an ecologic study in the world for 
assessment the correlation between age-specific incidence 
and mortality rate (ASR) of Bladder Cancer with Human 
Development Index (HDI) and its details that include: 
Life expectancy at birth, Mean years of schooling and 
Gross national income (GNI) per capita. Data about the 
age-specific incidence and mortality rate (ASR) for every 
country for year 2012 get from global cancer project 
that available in (http://globocan.iarc.fr/Default.aspx) 
and Human Development Index (HDI) from Human 
Development Report 2013(Malik, 2013) that include 
information about HDI and its details for every country 
in the word for year 2012. 
Method of estimate the age-specific Incidence and 
mortality rates in global cancer project by international 
agency for research on cancer 
Age-specific incidence rate estimate
The methods of estimation are country specific and 
the quality of the estimation depends upon the quality 
and on the amount of the information available for each 
country. In theory, there are as many methods as countries, 
and because of the variety and the complexity of these 
methods, an overall quality score for the incidence and 
mortality estimates combined is almost impossible to 
establish. However an alphanumeric scoring system which 
independently describes the availability of incidence 
and mortality data has been established at the country 
level. The combined score is presented together with the 
estimates for each country with an aim of providing a 
broad indication of the robustness of the estimation.
The methods to estimate the sex- and age-specific 
incidence rates of cancer for a specific country fall into 
one of the following broad categories, in priority order:
1- Rates projected to 2012 (38 countries)-2- Most 
recent rates applied to 2012 population (20 countries)-
3-Estimated from national mortality by modelling, using 
incidence mortality ratios derived from recorded data 
in country-specific cancer registries (13 countries)-4- 
Estimated from national mortality estimates by modelling, 
using incidence mortality ratios derived from recorded 
data in local cancer registries in neighboring countries (9 
European countries)-5-Estimated from national mortality 
estimates using modelled survival (32 countries)-6- 
Estimated as the weighted average of the local rates 
(16 countries)-7- One cancer registry covering part of a 
country is used as representative of the country profile (11 
countries)-8-Age/sex specific rates for “all cancers” were 
partitioned using data on relative frequency of different 
cancers (by age and sex) (12 countries)-9- The rates are 
those of neighboring countries or registries in the same 
area (33 countries). (Stewart and Wild, 2014; Ferlay et 
al., 2015)
Age-specific mortality rate estimate 
Depending of the degree of detail and accuracy of the 
national mortality data, six methods have been utilized in 
the following order of priority:
1-Rates projected to 2012 (69 countries)-2- Most 
recent rates applied to 2012 population (26 countries)-3- 
Estimated as the weighted average of regional rates (1 
country)-4- Estimated from national incidence estimates 
by modelling, using country-specific survival (2 
countries)-5-Estimated from national incidence estimates 
using modelled survival (83 countries)-6-The rates are 
those of neighboring countries or registries in the same 
area (3 countries) 
Human development index (HDI)
Human Development Index (HDI), a composite 
measure of indicators along three dimensions: life 
expectancy, educational attainment and command over 
the resources needed for a decent living. All groups 
and regions have seen notable improvement in all HDI 
components, with faster progress in low and medium 
HDI countries. On this basis, the world is becoming 
less unequal. Nevertheless, national averages hide large 
variations in human experience. Wide disparities remain 
within countries of both the North and the South, and 
income inequality within and between many countries 
has been rising.(Malik, 2013)
Statistical analysis: In this study, we use of correlation 
bivariate method for assessment the correlation between 
age-specific incidence and mortality rate (ASR) with 
Human Development Index (HDI) and its details that 
include: Life expectancy at birth, Mean years of schooling 
and Gross national income (GNI) per capita. Statistical 
significance was assumed if P< 0.05. All reported P-values 
are two-sided. Statistical analyses were performed using 
SPSS (Version 15.0, SPSS Inc).
Results 
The incidence of bladder cancer 
In 2012, 429,793 bladder cancer cases occurred in the 
world, so that there were 237,778 new cases in countries 
with very high HDI, 72,293 cases in countries with high 
HDI, 103,105 cases in countries with moderate HDI, 
and 16,407 cases in countries with low HDI. The highest 
number of cancer cases was seen in countries such as the 
United States with about 68,639 cases, China 55,486, 
Germany about 28,405, Japan 22,042, and Italy with 
about 18,284 cases, respectively. Five countries that had 
the largest number of bladder cancer in men were the 
United States about 52,099, China about 41,993, Germany 
21,656, Japan 16755, and Italy 14,674 cases, respectively. 
The highest number in women was seen in 5 countries 
including the United States about 16,540, China 13,493, 
Germany 6,749 cases, Japan 5,287, and Italy 3,610 cases, 
respectively.
The age- standardized incidence rate (ASIR)
The incidence rate in countries with very high HDI 
was 9.7 per 100,000, in countries with a high HDI 5.9 per 
100,000, in countries with medium HDI 2.9 per 100,000, 
and in countries with a low HDI 2.2 per 100,000. Five 
countries that had the highest age-standardized incidence 
were 
Belgium 17.5 per 100,000, Lebanon 16.6 100,000, 
Malta 15.8 per 100,000, Turkey 15.2 per 100,000, and 
Denmark 14.4 per 100,000, respectively. Five countries 
with the highest age-standardized incidence rate for men 
included Belgium 31 per 100,000, Lebanon 29.1 per 
100,000, Turkey 28.7 per 100,000, Armenia 27.3 per 
100,000, and Malta 26.9 per 100,000, respectively. Five 
countries also had the highest age-standardized incidence 
rate for women were Hungary 7.4 per 100,000, Denmark 
7.0 per 100,000, Norway 6.4 per 100,000, Belgium 6.2 
per 100,000, and Malta 6.2 per 100,000, respectively. 
(Figure 1,2)
The number of deaths from cancer
In 2012, 165,084 bladder death cases occurred in the 
world, so that there were 71,687 death cases in countries 
with very high HDI, 30,827 cases in countries with high 
HDI, 52,995 cases in countries with moderate HDI, and 
10,508 cases in countries with low HDI. The highest 
number of death cases was seen in countries such as China 
26,820 cases, the United States 16,468, India 9,523, Japan 
7,630, and Russia 6,843 cases, respectively. Five countries 
that had the largest number of death in men were China 
20,056, the United States 4,669, India 7,664, Russia 
5,352, and Japan 5,168 cases, respectively. The highest 
number in women was seen in 5 countries including China 
about 6,762, the United States 4,662, Japan 2,462 cases, 
Germany 1,861, and India 1,859 cases, respectively.
The age- standardized death rate (ASDR)
The age-standardized death rate in countries with 
very high HDI was 2.4 per 100,000, in countries with 
a high HDI 2.4 per 100,000, in countries with medium 
HDI 1.4 per 100,000, and in countries with a low HDI 
1.5 per 100,000. Five countries that had the highest age-
standardized death rate were Turkey 6.6 per 100,000, 
Egypt 6.5 100,000, Iraq 6.3 per 100,000, Lebanon 6.3 
per 100,000, and Mali 5.2 per 100,000, respectively. 
Five countries with the highest age-standardized death 
rate for men included Turkey 12.8 per 100,000, Iraq 11.4 
per 100,000, Armenia 1.3 per 100,000, Egypt 11.1 per 
100,000, and Lebanon 11 per 100,000, respectively. Five 
countries also had the highest age-standardized death 
rate for women were Mali 4.4 per 100,000, Malawi 4.4 
per 100,000, Malta 4.3 per 100,000, French Polynesia 
2.9 per 100,000, and Iraq 2.9 per 100,000, respectively. 
(Figure1,3)
Correlation analysis between the standardized incidence 
rate, and HD and its components
The results of correlation analysis showed a positive 
linear relationship between the standardized incidence 
rate and HDI (r=0.653, P<0.001). (Figure 4) A positive 
correlation was observed between HDI components and 
standardized incidence rate, so that there was a positive 
correlation between the standardized incidence rate 
and life expectancy at birth (r= 0.596, P<0.001), the 
standardized incidence rate and average years of schooling 
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Egypt, respectively. There was the lowest level in Sub-
Saharan Africa, Asia, and South America, respectively. 
The greatest mortality rates were in parts of Europe and 
North Africa, and the lowest in Asia, Central America, and 
Middle Africa. However, the incidence and mortality have 
decreased in many Western countries (North America, and 
West and Northern Europe), but the rates have increased 
in some other European countries (South, Central, and 
East Europe) and developing countries in Asia. This 
pattern is due to differences in risk factors for bladder 
cancer (tobacco epidemic, changes in coding practices, the 
prevalence of Schistosoma Haematobium, especially in 
Africa, and occupational exposures) (Chavan et al., 2014). 
The differences in risk factors are the most important 
reason for the difference in the incidence of and deaths 
from bladder cancer in the world. Risk factors for bladder 
cancer include smoking (responsible for 50% of bladder 
cancer and 65% of invasive bladder cancer (Klotz and 
Brausi, 2015)), infection with Schistosoma Haematobium, 
occupational exposures to aromatic amines and polycyclic 
aromatic hydrocarbons (Silverman et al., 2006; Burger 
et al., 2013), and other possible factors such as diet, 
environmental pollution, and genetic predisposition; 
while cigarette smoking is the dominant cause of bladder 
cancer in the United States and Schistosoma Haematobium 
the leading cause in most parts of Africa (Parkin, 2006; 
Burger et al., 2013). 
Bladder cancer is highly preventable (Burger et al., 
2013). Therefore, the urologists can easily affect the 
prevention of the cancer through interaction with their 
patients, primary care physicians and society (Klotz and 
Brausi, 2015). The Human Development Index (HDI) is a 
useful classification to compare the cancer globally (Bray 
et al., 2012; Ghoncheh et al., 2015). As a result, countries 
are classified in to 4 levels, low, medium, high and very 
high, by education, life expectancy, and national income. 
Although communicable diseases and nutrition are 
common causes of death in countries with a low HDI, Non-
communicable diseases such as cancer have overtaken 
(Wagner and Brath, 2012). It is predicted that the cancer 
burden in the world has increased from 12.7 million new 
cases in 2008 to 22.2 million by 2030 (Bray et al., 2012). 
It shows an increase in population and changes in the age 
distribution, the incidence, prevalence, and risk factors. 
For example, open tobacco use in low- and middle-income 
countries leads to a major effect on the cancer burden in 
the coming decades (Giovino et al., 2012). Several studies 
have shown that survival differences are associated with 
socioeconomic status of the patients (Coleman et al., 
2001; Brookfield et al., 2009; Trinh et al., 2012). People 
with low socio-economic status experience lower survival 
due to reduced access to health care, biology of the 
disease, environmental factors, exposure to tobacco, and 
health habits (Shackley and Clarke, 2005). Persons with 
extensive knowledge expose lower to bladder cancer risk 
factors, including smoking. This leads to lower bladder 
cancer in them (Yang et al., 2010). 
The information on the incidence and mortality of 
the disease, and its distribution in terms of geographical 
areas is essential for further studies and better plan for the 
prevention. There is no study to evaluate the incidence 
and mortality from the cancer in the world. Considering 
the relationship between the development and incidence 
and mortality from the cancer, the aim of the study was to 
investigate bladder cancer incidence and mortality rates, 
and their relationship with the HDI in the world. 
Materials and Methods
This study was an ecologic study in the world for 
assessment the correlation between age-specific incidence 
and mortality rate (ASR) of Bladder Cancer with Human 
Development Index (HDI) and its details that include: 
Life expectancy at birth, Mean years of schooling and 
Gross national income (GNI) per capita. Data about the 
age-specific incidence and mortality rate (ASR) for every 
country for year 2012 get from global cancer project 
that available in (http://globocan.iarc.fr/Default.aspx) 
and Human Development Index (HDI) from Human 
Development Report 2013(Malik, 2013) that include 
information about HDI and its details for every country 
in the word for year 2012. 
Method of estimate the age-specific Incidence and 
mortality rates in global cancer project by international 
agency for research on cancer 
Age-specific incidence rate estimate
The methods of estimation are country specific and 
the quality of the estimation depends upon the quality 
and on the amount of the information available for each 
country. In theory, there are as many methods as countries, 
and because of the variety and the complexity of these 
methods, an overall quality score for the incidence and 
mortality estimates combined is almost impossible to 
establish. However an alphanumeric scoring system which 
independently describes the availability of incidence 
and mortality data has been established at the country 
level. The combined score is presented together with the 
estimates for each country with an aim of providing a 
broad indication of the robustness of the estimation.
The methods to estimate the sex- and age-specific 
incidence rates of cancer for a specific country fall into 
one of the following broad categories, in priority order:
1- Rates projected to 2012 (38 countries)-2- Most 
recent rates applied to 2012 population (20 countries)-
3-Estimated from national mortality by modelling, using 
incidence mortality ratios derived from recorded data 
in country-specific cancer registries (13 countries)-4- 
Estimated from national mortality estimates by modelling, 
using incidence mortality ratios derived from recorded 
data in local cancer registries in neighboring countries (9 
European countries)-5-Estimated from national mortality 
estimates using modelled survival (32 countries)-6- 
Estimated as the weighted average of the local rates 
(16 countries)-7- One cancer registry covering part of a 
country is used as representative of the country profile (11 
countries)-8-Age/sex specific rates for “all cancers” were 
partitioned using data on relative frequency of different 
cancers (by age and sex) (12 countries)-9- The rates are 
those of neighboring countries or registries in the same 
area (33 countries). (Stewart and Wild, 2014; Ferlay et 
al., 2015)
Age-specific mortality rate estimate 
Depending of the degree of detail and accuracy of the 
national mortality data, six methods have been utilized in 
the following order of priority:
1-Rates projected to 2012 (69 countries)-2- Most 
recent rates applied to 2012 population (26 countries)-3- 
Estimated as the weighted average of regional rates (1 
country)-4- Estimated from national incidence estimates 
by modelling, using country-specific survival (2 
countries)-5-Estimated from national incidence estimates 
using modelled survival (83 countries)-6-The rates are 
those of neighboring countries or registries in the same 
area (3 countries) 
Human development index (HDI)
Human Development Index (HDI), a composite 
measure of indicators along three dimensions: life 
expectancy, educational attainment and command over 
the resources needed for a decent living. All groups 
and regions have seen notable improvement in all HDI 
components, with faster progress in low and medium 
HDI countries. On this basis, the world is becoming 
less unequal. Nevertheless, national averages hide large 
variations in human experience. Wide disparities remain 
within countries of both the North and the South, and 
income inequality within and between many countries 
has been rising.(Malik, 2013)
Statistical analysis: In this study, we use of correlation 
bivariate method for assessment the correlation between 
age-specific incidence and mortality rate (ASR) with 
Human Development Index (HDI) and its details that 
include: Life expectancy at birth, Mean years of schooling 
and Gross national income (GNI) per capita. Statistical 
significance was assumed if P< 0.05. All reported P-values 
are two-sided. Statistical analyses were performed using 
SPSS (Version 15.0, SPSS Inc).
Results 
The incidence of bladder cancer 
In 2012, 429,793 bladder cancer cases occurred in the 
world, so that there were 237,778 new cases in countries 
with very high HDI, 72,293 cases in countries with high 
HDI, 103,105 cases in countries with moderate HDI, 
and 16,407 cases in countries with low HDI. The highest 
number of cancer cases was seen in countries such as the 
United States with about 68,639 cases, China 55,486, 
Germany about 28,405, Japan 22,042, and Italy with 
about 18,284 cases, respectively. Five countries that had 
the largest number of bladder cancer in men were the 
United States about 52,099, China about 41,993, Germany 
21,656, Japan 16755, and Italy 14,674 cases, respectively. 
The highest number in women was seen in 5 countries 
including the United States about 16,540, China 13,493, 
Germany 6,749 cases, Japan 5,287, and Italy 3,610 cases, 
respectively.
The age- standardized incidence rate (ASIR)
The incidence rate in countries with very high HDI 
was 9.7 per 100,000, in countries with a high HDI 5.9 per 
100,000, in countries with medium HDI 2.9 per 100,000, 
and in countries with a low HDI 2.2 per 100,000. Five 
countries that had the highest age-standardized incidence 
were 
Belgium 17.5 per 100,000, Lebanon 16.6 100,000, 
Malta 15.8 per 100,000, Turkey 15.2 per 100,000, and 
Denmark 14.4 per 100,000, respectively. Five countries 
with the highest age-standardized incidence rate for men 
included Belgium 31 per 100,000, Lebanon 29.1 per 
100,000, Turkey 28.7 per 100,000, Armenia 27.3 per 
100,000, and Malta 26.9 per 100,000, respectively. Five 
countries also had the highest age-standardized incidence 
rate for women were Hungary 7.4 per 100,000, Denmark 
7.0 per 100,000, Norway 6.4 per 100,000, Belgium 6.2 
per 100,000, and Malta 6.2 per 100,000, respectively. 
(Figure 1,2)
The number of deaths from cancer
In 2012, 165,084 bladder death cases occurred in the 
world, so that there were 71,687 death cases in countries 
with very high HDI, 30,827 cases in countries with high 
HDI, 52,995 cases in countries with moderate HDI, and 
10,508 cases in countries with low HDI. The highest 
number of death cases was seen in countries such as China 
26,820 cases, the United States 16,468, India 9,523, Japan 
7,630, and Russia 6,843 cases, respectively. Five countries 
that had the largest number of death in men were China 
20,056, the United States 4,669, India 7,664, Russia 
5,352, and Japan 5,168 cases, respectively. The highest 
number in women was seen in 5 countries including China 
about 6,762, the United States 4,662, Japan 2,462 cases, 
Germany 1,861, and India 1,859 cases, respectively.
The age- standardized death rate (ASDR)
The age-standardized death rate in countries with 
very high HDI was 2.4 per 100,000, in countries with 
a high HDI 2.4 per 100,000, in countries with medium 
HDI 1.4 per 100,000, and in countries with a low HDI 
1.5 per 100,000. Five countries that had the highest age-
standardized death rate were Turkey 6.6 per 100,000, 
Egypt 6.5 100,000, Iraq 6.3 per 100,000, Lebanon 6.3 
per 100,000, and Mali 5.2 per 100,000, respectively. 
Five countries with the highest age-standardized death 
rate for men included Turkey 12.8 per 100,000, Iraq 11.4 
per 100,000, Armenia 1.3 per 100,000, Egypt 11.1 per 
100,000, and Lebanon 11 per 100,000, respectively. Five 
countries also had the highest age-standardized death 
rate for women were Mali 4.4 per 100,000, Malawi 4.4 
per 100,000, Malta 4.3 per 100,000, French Polynesia 
2.9 per 100,000, and Iraq 2.9 per 100,000, respectively. 
(Figure1,3)
Correlation analysis between the standardized incidence 
rate, and HD and its components
The results of correlation analysis showed a positive 
linear relationship between the standardized incidence 
rate and HDI (r=0.653, P<0.001). (Figure 4) A positive 
correlation was observed between HDI components and 
standardized incidence rate, so that there was a positive 
correlation between the standardized incidence rate 
and life expectancy at birth (r= 0.596, P<0.001), the 
standardized incidence rate and average years of schooling 
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(r= 0.578, P<0.001), and the standardized incidence rate 
and the level of income per person of population (r= 
0.487, P<0.001).
Correlation analysis between the standardized mortality 
rate, and HDI and its components 
The results of correlation analysis showed a positive 
linear relationship between the standardized mortality 
rate and HDI (r=0.308, P<0.001). (Figure 5) A positive 
correlation was observed between HDI components and 
standardized mortality rate, so that there was a positive 
correlation between the standardized mortality rate and life 
expectancy at birth (r= 0.292, P<0.001), the standardized 
mortality rate and average years of schooling (r= 0.244, 
P<0.001) and the standardized mortality rate and the level 
of income per person of population (r= 0.172, P<0.001).
Discussion
There were more than 900,000 new cases of bladder 
cancer per year, and approximately 250,000 deaths occur 
from the cancer worldwide (Klotz and Brausi, 2015). 
In addition to the human toll, the prevalence of bladder 
cancer is associated with the economic burden on global 
health care systems (Measuring the burden is based on the 
overall cost of patient from diagnosis to death. Bladder 
cancer is one of the most expensive cancers in terms of 
treatment (Sievert et al., 2009). Considering the aging 
population and its impact on the burden of cancer, this 
cancer is significant and requires special attention (Ploeg 
et al., 2009).
Our results showed that the highest standardized 
incidence rate of bladder cancer was related to Belgium, 
Lebanon, Malta, Turkey, and Denmark, respectively. In 
this study, a strong correlation was observed between HDI 
and incidence of bladder cancer. Other studies have also 
shown that the incidence of bladder cancer was associated 
with a significant difference in high HDI countries than 
countries with low HDI, but there was a little difference 
in terms of mortality rate (Bray et al., 2012). 
The highest incidence of bladder cancer was seen 
in developed countries and parts of Africa, while the 
highest mortality rate was related to the North African 
countries of the Middle East. The difference in bladder 
cancer incidence and mortality in countries around the 
world is due to differences in known risk factors, coding, 
detection, diagnosis practices, and access to health care 
(Chavan et al., 2014). Greater access to health care and 
better treatment is one of the causes of lower death in 
countries with higher HDI (Ploeg et al., 2009).
Smoking is the most important risk factors for bladder 
cancer in most parts of the world (Silverman et al., 2006), 
so that the attributable risk is 50% in Europe (Agudo et 
al., 2012). In a meta-analysis, it has been recently seen 
that smoking is associated with a threefold increase in 
the risk of lower urinary tract cancer, particularly bladder 
(Gandini et al., 2008). About 90% of cases with bladder 
cancer result from smoking (Kaufman et al., 2009). The 
increase in the incidence and mortality in women in some 
Eastern European countries is because of the prevalence 
of cigarette smoking(Chavan et al., 2014). Reduced 
mortality rate in Western countries is due to decreasing the 
prevalence of tobacco use (Chavan et al., 2014), so that 
the prevalence of smoking decreased in American adults 
in 1965 from about 45% to about 19% in 2010 (Jemal 
et al., 2008). As well as, a significant reduction has also 
reported from Canada and Australia (Gilmore, 2002; July 
24, 2012). In developed and Western countries, few studies 
showed that the reduction in the incidence of bladder 
cancer has been attributed to decreasing of occupational 
exposures (Pelucchi et al., 2006; Ferlay et al., 2008; Cirla 
et al., 2011). A relatively high incidence of bladder cancer 
in North Africa has been largely attributed to the parasite 
Schistosoma Haematobium. Egypt is a good example in 
this regard so that the control of S. Haematobium declined 
cases of bladder cancer (Salem and Mahfouz, 2012). 
Reduced mortality in these countries is due to controlling 
S. Haematobium and improving sanitation and hygiene 
(Chavan et al., 2014). 
In our study, a significant positive relationship 
was observed between life expectancy as one of the 
components of the HDI and the standardized incidence and 
mortality rates. In other studies, with increased average 
life expectancy, the incidence of bladder cancer increased 
in the elderly (Yuge et al., 2011). Life expectancy is 
more in women than in men with similar age and race. 
For example, in 2006, life expectancy for a 70 year old 
white men with bladder cancer was 13.6, but in a white 
women 70 years 15.9 (March 2011). It can be concluded 
that bladder cancer is related to elderly. Considering aging 
populations, the incidence of the cancer will increase. 
Hence, it is necessary to pay more attention and studies 
on the etiology.
One of the components of HDI is access to knowledge, 
which is specified by the average years of schooling. In 
our study, a significant positive correlation was observed 
between the education level and standardized incidence 
and mortality rates. Other studies also found a significant 
positive correlation between level of education and 
bladder cancer(Hussain et al., 2008) . Education levels 
may be related to behavior, health conditions, access to 
knowledge, and resources that directly or indirectly affects 
the cancer (Spiegel et al., 1989; Kogevinas M, 1997; 
Spiegel, 2002; Spiegel and Giese-Davis, 2003; Lehto et 
al., 2006; van Vliet et al., 2006; Griggs et al., 2007). 
Another component of HDI is the income level, which 
is determined by the Gross National Product (GDP). In 
our study, there was a significant positive relationship 
between the income level, and the standardized incidence 
and mortality rates. A strong correlation between 
socioeconomic status and survival of patients with bladder 
cancer has been observed in other studies. In other words, 
the increase in premature death was seen in patients 
with low socioeconomic status than those with higher 
socioeconomic status (Siddiqui et al., 2015). The patients 
with low socio-economic status experience lower survival 
due to reduced access to health care, biology of the disease, 
environmental factors, exposure to tobacco, and health 
habits (Shackley and Clarke, 2005). Thus, reducing the 
incidence and mortality from the cancer in all countries 
is possible using interventions such as tobacco control, 
improved sanitation and hygiene to reduce infection with 
S. Haematobium, improving safety of workplaces, and 
decreasing occupational exposures (Chavan et al., 2014). 
In conclusion, The incidence of bladder cancer in 
developed countries and parts of Africa was higher, 
while the highest mortality rate was observed in the 
countries of North Africa and the Middle East .there was 
statistically a significant positive correlation between 
the standardized incidence rate of bladder cancer, and 
the HDI, and its components, including life expectancy 
at birth, the average level of education, and the income 
level per person. A significant positive correlation was 
observed between standardized mortality rate, and the HDI 
and its components. The program for better treatment in 
developing countries to reduce mortality from the cancer 
and studies on the etiology of incidence and mortality 
are essential.
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(r= 0.578, P<0.001), and the standardized incidence rate 
and the level of income per person of population (r= 
0.487, P<0.001).
Correlation analysis between the standardized mortality 
rate, and HDI and its components 
The results of correlation analysis showed a positive 
linear relationship between the standardized mortality 
rate and HDI (r=0.308, P<0.001). (Figure 5) A positive 
correlation was observed between HDI components and 
standardized mortality rate, so that there was a positive 
correlation between the standardized mortality rate and life 
expectancy at birth (r= 0.292, P<0.001), the standardized 
mortality rate and average years of schooling (r= 0.244, 
P<0.001) and the standardized mortality rate and the level 
of income per person of population (r= 0.172, P<0.001).
Discussion
There were more than 900,000 new cases of bladder 
cancer per year, and approximately 250,000 deaths occur 
from the cancer worldwide (Klotz and Brausi, 2015). 
In addition to the human toll, the prevalence of bladder 
cancer is associated with the economic burden on global 
health care systems (Measuring the burden is based on the 
overall cost of patient from diagnosis to death. Bladder 
cancer is one of the most expensive cancers in terms of 
treatment (Sievert et al., 2009). Considering the aging 
population and its impact on the burden of cancer, this 
cancer is significant and requires special attention (Ploeg 
et al., 2009).
Our results showed that the highest standardized 
incidence rate of bladder cancer was related to Belgium, 
Lebanon, Malta, Turkey, and Denmark, respectively. In 
this study, a strong correlation was observed between HDI 
and incidence of bladder cancer. Other studies have also 
shown that the incidence of bladder cancer was associated 
with a significant difference in high HDI countries than 
countries with low HDI, but there was a little difference 
in terms of mortality rate (Bray et al., 2012). 
The highest incidence of bladder cancer was seen 
in developed countries and parts of Africa, while the 
highest mortality rate was related to the North African 
countries of the Middle East. The difference in bladder 
cancer incidence and mortality in countries around the 
world is due to differences in known risk factors, coding, 
detection, diagnosis practices, and access to health care 
(Chavan et al., 2014). Greater access to health care and 
better treatment is one of the causes of lower death in 
countries with higher HDI (Ploeg et al., 2009).
Smoking is the most important risk factors for bladder 
cancer in most parts of the world (Silverman et al., 2006), 
so that the attributable risk is 50% in Europe (Agudo et 
al., 2012). In a meta-analysis, it has been recently seen 
that smoking is associated with a threefold increase in 
the risk of lower urinary tract cancer, particularly bladder 
(Gandini et al., 2008). About 90% of cases with bladder 
cancer result from smoking (Kaufman et al., 2009). The 
increase in the incidence and mortality in women in some 
Eastern European countries is because of the prevalence 
of cigarette smoking(Chavan et al., 2014). Reduced 
mortality rate in Western countries is due to decreasing the 
prevalence of tobacco use (Chavan et al., 2014), so that 
the prevalence of smoking decreased in American adults 
in 1965 from about 45% to about 19% in 2010 (Jemal 
et al., 2008). As well as, a significant reduction has also 
reported from Canada and Australia (Gilmore, 2002; July 
24, 2012). In developed and Western countries, few studies 
showed that the reduction in the incidence of bladder 
cancer has been attributed to decreasing of occupational 
exposures (Pelucchi et al., 2006; Ferlay et al., 2008; Cirla 
et al., 2011). A relatively high incidence of bladder cancer 
in North Africa has been largely attributed to the parasite 
Schistosoma Haematobium. Egypt is a good example in 
this regard so that the control of S. Haematobium declined 
cases of bladder cancer (Salem and Mahfouz, 2012). 
Reduced mortality in these countries is due to controlling 
S. Haematobium and improving sanitation and hygiene 
(Chavan et al., 2014). 
In our study, a significant positive relationship 
was observed between life expectancy as one of the 
components of the HDI and the standardized incidence and 
mortality rates. In other studies, with increased average 
life expectancy, the incidence of bladder cancer increased 
in the elderly (Yuge et al., 2011). Life expectancy is 
more in women than in men with similar age and race. 
For example, in 2006, life expectancy for a 70 year old 
white men with bladder cancer was 13.6, but in a white 
women 70 years 15.9 (March 2011). It can be concluded 
that bladder cancer is related to elderly. Considering aging 
populations, the incidence of the cancer will increase. 
Hence, it is necessary to pay more attention and studies 
on the etiology.
One of the components of HDI is access to knowledge, 
which is specified by the average years of schooling. In 
our study, a significant positive correlation was observed 
between the education level and standardized incidence 
and mortality rates. Other studies also found a significant 
positive correlation between level of education and 
bladder cancer(Hussain et al., 2008) . Education levels 
may be related to behavior, health conditions, access to 
knowledge, and resources that directly or indirectly affects 
the cancer (Spiegel et al., 1989; Kogevinas M, 1997; 
Spiegel, 2002; Spiegel and Giese-Davis, 2003; Lehto et 
al., 2006; van Vliet et al., 2006; Griggs et al., 2007). 
Another component of HDI is the income level, which 
is determined by the Gross National Product (GDP). In 
our study, there was a significant positive relationship 
between the income level, and the standardized incidence 
and mortality rates. A strong correlation between 
socioeconomic status and survival of patients with bladder 
cancer has been observed in other studies. In other words, 
the increase in premature death was seen in patients 
with low socioeconomic status than those with higher 
socioeconomic status (Siddiqui et al., 2015). The patients 
with low socio-economic status experience lower survival 
due to reduced access to health care, biology of the disease, 
environmental factors, exposure to tobacco, and health 
habits (Shackley and Clarke, 2005). Thus, reducing the 
incidence and mortality from the cancer in all countries 
is possible using interventions such as tobacco control, 
improved sanitation and hygiene to reduce infection with 
S. Haematobium, improving safety of workplaces, and 
decreasing occupational exposures (Chavan et al., 2014). 
In conclusion, The incidence of bladder cancer in 
developed countries and parts of Africa was higher, 
while the highest mortality rate was observed in the 
countries of North Africa and the Middle East .there was 
statistically a significant positive correlation between 
the standardized incidence rate of bladder cancer, and 
the HDI, and its components, including life expectancy 
at birth, the average level of education, and the income 
level per person. A significant positive correlation was 
observed between standardized mortality rate, and the HDI 
and its components. The program for better treatment in 
developing countries to reduce mortality from the cancer 
and studies on the etiology of incidence and mortality 
are essential.
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